Read Original Release

UNC PR release offers platitudes, but few facts, on new cochlear implant for adults

UNC Hearing Loss Experts Lead Clinical Trials of FDA-Approved Hearing Implant

Our Review Summary

Synchrony EAS (electric acoustic stimulation) hearing implant

Synchrony EAS (electric acoustic stimulation) hearing implant. Image credit: Med-El USA, the device manufacturer

This news release from the University of North Carolina purports to advise journalists and the public about clinical research from the university that helped gain recent FDA approval for an implantable hearing device designed for adults with a form of moderate to severe hearing loss. But this news release is a not-very-thinly veiled infomercial for the device’s maker, and a promotional piece for and by the head of the university department whose faculty members clearly stand to benefit from marketing it. The release is full of hyperbolic praise for the device (“The technology is remarkable and so were the results…”) and the university’s role in the clinical trials. But it is very light on quantitative data and information about costs, complications and side effects that would help readers judge the pros and cons of an invasive cochlear implant.

The release offers no links or references to published, peer-reviewed data; to the manufacturer’s website; or notes on potential conflicts of interest. There is some useful information about the prevalence of hearing loss in the U.S. and about what is novel about the implant. But this releases reads more like a commercial brochure than an informative and educational summary for public awareness.

 

Why This Matters

Hearing loss is indeed a significant and growing problem and a threat to an aging population. In recent years, hearing loss has been tied by research to cognitive loss (as described in this 2013 study published in JAMA Internal Medicine), as well as social isolation, traffic accidents and a host of other physical, emotional and social ills. Because Medicare, Medicaid and other insurers do not cover the cost of hearing aids — which can run into the thousands of dollars for state-of-the-art devices — most adults who need them don’t have them. For the most severe, disabling forms of “sensorineural”  hearing loss, cochlear implants can be life-changing, and the device described in this release could have novelty and benefits in addressing both high and low frequency hearing problems. Significantly, most insurance, including Medicare, covers the cost of the device and implant surgery.  But the benefits of the implants come with risks, including the need for general anesthesia, damage to facial nerves, infections, tinnitus, and numbness. Adjustment to the devices can take months of habilitative services — and removal rates remain high in some populations. Long-term effects, moreover, still are largely unknown.

For all these reasons, news releases and stories about surgical implants should offer context about the benefits, risks, costs and alternatives.

Criteria

Does the news release adequately discuss the costs of the intervention?

Not Satisfactory

Neither the release nor a company web site, nor a Google search turned up information about the cost of the approved device. There are almost always out-of-pocket costs associated with implants, even when insurance coverage is good.

Does the news release adequately quantify the benefits of the treatment/test/product/procedure?

Not Satisfactory

The release claims that 97 percent of participants in the clinical trial at UNC “reported a benefit” from the device within the first year and 90 percent reported overall satisfaction. It says “on average, patients performed more than twice as well on tests of speech understanding” compared to those without the implant.

It is not clear if the benefit experienced by 97 percent of participants translated into clinical (real-life) significance for patients. What exactly does “satisfaction” represent in this context? The release doesn’t specify. And how big a benefit is performing “twice as well” as patients who didn’t get the device? The answer depends on what the baseline hearing losses were for each group of participants — something not discussed in the release. There are no data at all on failures, removals, infections, etc. They are not mentioned.

Does the news release adequately explain/quantify the harms of the intervention?

Not Satisfactory

The release has zero information about harms, actual or potential.

Does the news release seem to grasp the quality of the evidence?

Not Satisfactory

Readers of this release never learn anything about the age, gender, socioeconomic status, educational background, or race of participants. Nothing is learned about the implant procedure, evaluation of the patients, how participants were selected, or how they were followed in after-implant care. In short, the release doesn’t offer any particulars about the clinical research protocol that the university treated “more of” than any other participating hearing center. We can assume that the study involved multiple sites but not much more.

Does the news release commit disease-mongering?

Satisfactory

There is no mongering and to its credit, the release provides concrete statistics on the prevalence of hearing loss. But there is some evidence of “benefits mongering.”

Does the news release identify funding sources & disclose conflicts of interest?

Not Satisfactory

The release needed information about funding sources for the clinical trials. In addition, the release does not explain the quoted source’s relationship to the study (although it is implied that he is helping to lead it).

Does the news release compare the new approach with existing alternatives?

Not Satisfactory

Although the release makes some distinction between the type of hearing loss most likely to benefit from this FDA approved device; and it explains in some detail how the device is an improvement over other cochlear implants, it isn’t clear about the overlapping benefits of newer digital hearing aids and the implants for people in the “moderate” sensorineural hearing loss category.

Does the news release establish the availability of the treatment/test/product/procedure?

Satisfactory

The release notes that the device received FDA approval on September 16.and that it will be available “in coming months.”

Does the news release establish the true novelty of the approach?

Satisfactory

The release does a good job of explaining what is different about this device compared to other cochlear implants, notably that it is combines two technologies to address both high frequency and low frequency hearing loss. But the release would have been strengthened by noting that newer “open fit”  hearing aids also try to tackle the dual hearing loss problem for many people.

Does the news release include unjustifiable, sensational language, including in the quotes of researchers?

Satisfactory

The release doesn’t rely heavily sensational language.

Total Score: 4 of 10 Satisfactory

Comments

We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.

We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.